Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer

Nutrition and Cancer

Volumn 59, Issue 1, 2007, Pages 14-20

  Cerchietti, Leandro C A ^a,b   Navigante, Alfredo H ^a   Castro, Monica A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BODY WEIGHT; CACHEXIA; CELL INTERACTION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIETARY INTAKE; EVALUATION RESEARCH; FATIGUE; FEMALE; FISH; HUMAN; HYPERCALCEMIA; LUNG CANCER; MALE; METABOLIC SYNDROME X; MUSCLE STRENGTH; NAUSEA; PARANEOPLASTIC SYNDROME; PATHOPHYSIOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SATIETY; STROMA CELL; SYSTEMIC IMMUNE METABOLIC SYNDROME; WEAKNESS;

EID: 35148818281     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701365068     Document Type: Article

References (48)

1. Miaskowski C, Dodd M, and Lee K: Symptom clusters: the new frontier in symptom management research. J Natl Cancer Inst Monogr 32, 17-21, 2004.
2. Fleishman SB: Treatment of symptom clusters: pain, depression, and fatigue. J Natl Cancer Inst Monogr 32, 119-123, 2004.
3. Chan CW, Richardson A, and Richardson J: A study to assess the existence of the symptom cluster of breathlessness, fatigue and anxiety in patients with advanced lung cancer. Eur J Oncol Nurs 9, 325-333, 2005.
4. Cerchietti LC, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, et al.: Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27, 85-95, 2004.
5. Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8, 265-269, 2005.
6. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, et al.: Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 7, 427-434, 2004.
7. Seljelid R, Jozefowski S, and Sveinbjornsson B: Tumor stroma. Anti-cancer Res 19, 4809-4822, 1999.
8. Illman J, Corringham R, Robinson D Jr, Davis HM, Rossi JF, et al.: Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 3, 37-50, 2005.
9. Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, et al.: Cytokine-induced sickness behavior. Brain Behav Immun 17(Suppl 1), S112-S118, 2003.
10. Diament MJ, Peluffo GD, Stillitani I, Cerchietti LC, Navigante A, et al.: Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer Invest 24, 126-131, 2006.
11. Negri DR, Mezzanzanica D, Sacco S, Gadina M, Benigni F, et al.: Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine 15, 27-38, 2001.
12. Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, et al.: Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther 308, 929-934, 2004.
13. Wang W, Andersson M, Lonnroth C, Svanberg E, and Lundholm K: Prostaglandin E and prostacyclin receptor expression in tumor and host tissues from MCG 101-bearing mice: a model with prostanoid-related cachexia. Int J Cancer 115, 582-590, 2005.
14. Wang W, Andersson M, Lonnroth C, Svanberg E, and Lundholm K: Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia. J Exp Clin Cancer Res 24, 99-107, 2005.
15. Graves E, Ramsay E, and McCarthy DO: Inhibitors of COX activity preserve muscle mass in mice bearing the Lewis lung carcinoma, but not the B16 melanoma. Res Nurs Health 29, 87-97, 2006.
16. Zhou W, Jiang ZW, Tian J, Jiang J, Li N, et al.: Role of NF-kappaB and cytokine in experimental cancer cachexia. World J Gastroenterol 9, 1567-1570, 2003.
17. Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, et al.: Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 B1 background and eicosanoid-dependent cachexia. Cancer Res 60, 5488-5493, 2000.
18. Cahlin C, Gelin J, Delbro D, Lonnroth C, Doi C, et al.: Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 60, 1742-1749, 2000.
19. Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso MR, et al.: A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 15, 1030-1034, 2006.
20. Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, et al.: Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 11, 5802-5808, 2005.
21. Mantovani G, Maccio A, Mura L, Massa E, Mudu MC, et al.: Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78, 554-561, 2000.
22. Lundholm K, Daneryd P, Korner U, Hyltander A, and Bosaeus I: Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24, 505-512, 2004.
23. Argiles JM, Busquets S, and Lopez-Soriano FJ: Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res 130, 199-217, 2006.
24. Delano MJ and Moldawer LL: The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 21, 68-81, 2006.
25. Argiles JM, Busquets S, and Lopez-Soriano FJ: The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 37, 2036-2046, 2005.
26. Ross JA and Fearon KC: Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 5, 241-248, 2002.
27. Ferreira SH and Vane JR: Prostaglandins: their disappearance from and release into the circulation. Nature 216, 868-873, 1967.
28. Homem-de-Bittencourt Junior PI, Pontieri V, Curi R, and Lopes OU: Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats. Braz J Med Biol Res 22, 1039-1042, 1989.
29. Okamoto T: NSAID zaltoprofen improves the decrease in body weight in rodent sickness behavior models: proposed new applications of NSAIDs (Review). Int J Mol Med 9, 369-372, 2002.
30. McCarthy DO, Whitney P, Hitt A, and Al-Majid S: Indomethacin and Ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. Res Nurs Health 27, 174-184, 2004.
31. Moldawer LL and Copeland EM 3rd: Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 79, 1828-1839, 1997.
32. McMillan DC, O'Gorman P, Fearon KC, and McArdle CS: A pilot study of megestrol acetate and Ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 76, 788-790, 1997.
33. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, et al.: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54, 5602-5606, 1994.
34. Catella-Lawson F and Crofford LJ: Cyclooxygenase inhibition and thrombogenicity. Am J Med 110(Suppl3A), 28S-32S, 2001.
35. Lipsky PE, Abramson SB, Breedveld FC, Brook P, Burmester R, et al.: Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 27, 1338-1340, 2000.
36. Linenberger ML and Wittkowsky AK: Thromboembolic complications of malignancy: Part 1. Risks. Oncology (Williston Park) 19, 853-861, 2005.
37. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, et al.: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75, 2077-2082, 1995.
38. Pepys MB and Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 111, 1805-1812, 2003.
39. Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, et al.: Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer 101, 370-378, 2004.
40. Moses AW, Slater C, Preston T, Barber MD, and Fearon KC: Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90, 996-1002, 2004.
41. Suzuki S, Akechi T, Kobayashi M, Taniguchi K, Goto K, et al.: Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br J Cancer 90, 787-793, 2004.
42. Laviano A, Muscaritoli M, and Rossi-Fanelli F: Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia: a Cancer and Leukemia Group B study. Cancer 103, 651-652, 2005.
43. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, et al.: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12, S27-S30, 1996.
44. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, and Fearon KC: Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36, 177-184, 2000.
45. Bruera E, Strasser F, Palmer JL, Willey J, Calder K, et al.: Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 21, 129-134, 2003.
46. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, et al.: An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22, 2469-2476, 2004.
47. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, et al.: Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24, 3401-3407, 2006.
48. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479-1486, 2003.